Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2008-004013-94
    Sponsor's Protocol Code Number:MO22004
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2009-11-20
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2008-004013-94
    A.3Full title of the trial
    Estudio fase II prospectivo para evaluar alteraciones en biomarcadores moleculares y la administración de trastuzumab tras progresión a la exposición inicial de trastuzumab-taxano en pacientes diagnosticadas de cáncer de mama metastásico HER2-positivo
    A prospective Phase II study to evaluate alterations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression after initial exposure to trastuzumab-taxane based treatment
    A.3.2Name or abbreviated title of the trial where available
    SHERsig
    A.4.1Sponsor's protocol code numberMO22004
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorF. Hoffmann-La Roche Ltd.
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name HERCEPTIN 150 mg polvo para concentrado para solución para perfusión
    D.2.1.1.2Name of the Marketing Authorisation holderROCHE REGISTRATION LIMITED
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTRASTUZUMAB
    D.3.9.1CAS number 180288-69-1
    D.3.9.3Other descriptive nameTRASTUZUMAB
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeAnticuerpo Monoclonal Humanizado
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name XELODA 500 mg comprimidos recubiertos con película
    D.2.1.1.2Name of the Marketing Authorisation holderROCHE REGISTRATION LIMITED
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCAPECITABINA
    D.3.9.1CAS number 154361-50-9
    D.3.9.3Other descriptive nameCAPECITABINE
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Tratamiento de pacientes con cáncer de mama metastásico HER2-positivo
    Treatment of patients with HER2-positive metastatic breast cancer
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 9.1
    E.1.2Level LLT
    E.1.2Classification code 10065430
    E.1.2Term HER-2 positive breast cancer
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    1. Investigar y definir potencialmente firmas de biomarcadores moleculares que podrían experimentar alteraciones durante un tratamiento dirigido contra HER2 y predecir la mayor o menor sensibilidad al tratamiento con trastuzumab. Las firmas de los biomarcadores se correlacionarán con las variables de eficacia siguientes: Tiempo hasta la progresión (TPT), supervivencia libre de progresión (SLP) e tasa de respuesta global (RG) durante las partes 1 y 2 del estudio, basándose en la población por protocolo.
    E.2.2Secondary objectives of the trial
    Eficacia:
    1. TPT, SLP e RG (en las pacientes con enfermedad medible), en las partes 1 y 2 del estudio.
    2. Supervivencia global (SG).
    Seguridad:
    3. Seguridad de las biopsias en serie en mujeres con cáncer de mama metastásico.
    4. Seguridad de los tratamientos del estudio en las partes 1 y 2.
    Objetivos exploratorios:
    Se podrían investigar las correlaciones entre los diferentes biomarcadores evaluados, si se considera apropiado.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Obtención del consentimiento informado por escrito y firmado antes de iniciar los procedimientos específicos del protocolo.
    2. Mujeres de &#8805;18 años de edad.
    3. Presentar cáncer de mama metastásico evaluable, con o sin enfermedad medible, y al menos una lesión metastásica en la que se puedan realizar múltiples biopsias con aguja gruesa.
    4. Lesión metastásica HER2-positivo, definida por una puntuación 3+ en IHC y/o positividad en ISH (FISH, CISH o SISH), confirmada en el análisis del laboratorio central.
    5. Todas las muestras de biopsias tumorales deben estar disponibles para analizar en el laboratorio central.
    6. Estado funcional ECOG &#61603; 2.
    E.4Principal exclusion criteria
    Tratamientos previos o actuales
    1.Quimioterapia previa para enfermedad metastásica.
    2.Tratamiento previo basado en trastuzumab para cáncer de mama metastásico.
    3.Tratamiento previo con capecitabina.
    4.Tratamiento previo adyuvante/neoadyuvante con trastuzumab o adyuvante con bevacizumab o con un inhibidor de tirosina quinasa (TKI), que se haya completado <6 meses antes de administrar el primer tratamiento del estudio.
    5.Administración previa de dosis > 360 mg/m2 de doxorubicina o 720 mg/m2 de epirubicina o equivalentes.
    6.Tratamiento previo adyuvante con taxanos que se haya completado <12 meses antes de administrar el primer tratamiento del estudio.
    7.Biopsia de la lesión metastásica o de mama sólo por aspiración con aguja fina.
    8Enfermedad metastásica localizada únicamente en el SNC.
    9.Administración de inmunoterapia o tratamiento anticanceroso con agentes biológicos en los 21 días previos a la inclusión en el estudio.
    10.Administración de anticoagulantes por vía oral o parenteral en los 7 días previos a la biopsia basal y/o perfil de coagulación fuera del rango de normalidad de laboratorio en las 48 horas previas a la biopsia basal.
    11.Tratamiento concomitante con otros fármacos en investigación. Participación en otro ensayo clínico con cualquier fármaco en investigación en los 30 días previos a la evaluación de selección.
    12.Tratamiento concomitante con inmunoterapia u hormonoterapia para cáncer.
    Laboratorio
    13.Función de médula ósea inadecuada: RAN < 1,5 x 109/l, recuento de plaquetas < 100 x 109/l o Hb < 9 g/dl.
    14.Función renal inadecuada: creatinina sérica > 2,0 mg/dl o 177 &#956;mol/l.
    15.Función hepática inadecuada:
    obilirrubina sérica (total) > 1,5 x LSN,
    oAST y ALT > 3 x LSN (>6 x LSN en pacientes con metástasis hepáticas),
    oAST o ALT > 3 x LSN, acompañado de concentraciones séricas de fosfatasa alcalina > 6 x LSN en la evaluación basal.
    Afecciones previas o concomitantes
    16.Enfermedades concurrentes graves que pudieran afectar al cumplimiento del protocolo o la interpretación de los resultados, incluyendo las siguientes sin que esta relación sea exhaustiva:
    •Diátesis hemorrágica;
    •Condiciones comórbidas que no permitan interrumpir un tratamiento antiplaquetario (tal como clopidigrel, aspirina) en los 7 días anteriores y posteriores a las biopsias con aguja gruesa en serie;
    •Neuropatía periférica existente de grado > 2 NCI debida a cualquier causa;
    •Infección activa que requiera antibióticos;
    •Hipertensión no controlada (sistólica > 150 mm Hg y/o diastólica > 100 mm Hg);
    •Enfermedad cardiovascular clínicamente significativa: accidente cerebrovascular / ictus (en los &#8804; 6 meses previos a la inclusión en el estudio), infarto de miocardio (en los &#8804; 6 meses previos a la inclusión en el estudio), angina de pecho inestable, insuficiencia cardíaca congestiva de clase 2 o superior de acuerdo con la clasificación de la New York Heart Association (NYHA), arritmias cardíacas graves que requieran medicación;
    •Disnea en reposo que requiera oxigenoterapia de soporte o acompañada de derrames pleurales significativos;
    •Pacientes que requieran tratamiento diario crónico con corticosteroides (dosis equivalente a >10 mg/día de metilprednisolona) (exceptuando esteroides administrados por vía inhalatoria).
    17.Toxicidad cardíaca durante un tratamiento previo con trastuzumab que requirió la suspensión de este fármaco.
    18.Fracción de eyección ventricular izquierda (FEVI) < 50% en ecocardiograma o MUGA.
    19.Evidencia de cualquier otra enfermedad intercurrente grave, trastorno metabólico o psicológico, hallazgo en la exploración física o en las pruebas de laboratorio clínico o condición sociológica o geográfica, para los que estaría contraindicado el uso de un fármaco en investigación o que impedirían realizar un seguimiento adecuado y cumplir con los requisitos del protocolo del estudio.
    20.Antecedentes de otras neoplasias que pudieran afectar al cumplimiento del protocolo o la interpretación de los resultados. Las pacientes con cáncer tratadas con intención curativa (incluyendo tratamiento para cáncer de mama contralateral invasivo o in situ) podrán participar generalmente en el estudio si se han mantenido libres de enfermedad durante al menos 5 años, así como las pacientes con carcinoma in situ de cérvix o cáncer de piel no melanomatoso tratadas con intención curativa.
    21.Síndrome de malabsorción, enfermedades que afecten significativamente a la función gastrointestinal, resección del estómago o intestino delgado, o colitis ulcerativa.
    22.Hipersensibilidad confirmada a cualquiera de los fármacos del estudio o sus excipientes.
    23.Deficiencia confirmada de dihidropirimidina deshidrogenasa (DPD).
    Otros
    24.Mujeres embarazadas o en período de lactancia.
    25.Mujeres potencialmente fértiles (que se definen como aquellas que han tenido la última menstruación hace menos de 2 años) que no presenten un resultado negativo en la prueba de embarazo realiza
    26.Pacientes aptas para participar
    E.5 End points
    E.5.1Primary end point(s)
    1. Investigar y definir potencialmente firmas de biomarcadores moleculares que podrían experimentar alteraciones durante un tratamiento dirigido contra HER2 y predecir la mayor o menor sensibilidad al tratamiento con trastuzumab. Las firmas de los biomarcadores se correlacionarán con las variables de eficacia siguientes: Tiempo hasta la progresión (TP), supervivencia libre de progresión (SLP) e índice de respuesta global (IRG) durante las partes 1 y 2 del estudio, basándose en la población por protocolo.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    estudio de Biomarcadores
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans Information not present in EudraCT
    E.7.1.2Bioequivalence study Information not present in EudraCT
    E.7.1.3Other Information not present in EudraCT
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Information not present in EudraCT
    E.8.1.2Open Information not present in EudraCT
    E.8.1.3Single blind Information not present in EudraCT
    E.8.1.4Double blind Information not present in EudraCT
    E.8.1.5Parallel group Information not present in EudraCT
    E.8.1.6Cross over Information not present in EudraCT
    E.8.1.7Other Information not present in EudraCT
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Information not present in EudraCT
    E.8.2.3Other Information not present in EudraCT
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA8
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 38
    F.4.2.2In the whole clinical trial 50
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2010-01-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2009-12-18
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 10:43:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA